Adaptive Biotechnologies Corp. Hits New 52-Week High at $15.04

Adaptive Biotechnologies Corp. has reached a significant milestone by hitting a new 52-week high of USD 15.04 on September 30, 2025. This achievement marks a remarkable performance over the past year, with the stock soaring by 328.65%, significantly outpacing the S&P 500's growth of 16.09% during the same period.
As a small-cap company in the Pharmaceuticals & Biotechnology sector, Adaptive Biotechnologies Corp. has demonstrated strong momentum, reflecting its position in a competitive market. The company's market capitalization stands at USD 1,910 million, indicating its growing presence in the industry. Despite being loss-making, the stock's impressive price-to-book ratio of 10.63 suggests that investors are valuing the company's potential for future growth.

With a debt-to-equity ratio of -0.30 and a return on equity of -67.30%, the financial metrics highlight the company's current operational dynamics. The absence of a dividend yield further emphasizes its focus on reinvestment and growth. Overall, the achievement of this new high underscores Adaptive Biotechnologies Corp.'s notable performance in the market.